Pfizer's New Drugs Drive Q1 Earnings Beat
Pfizer reported Q1 2026 revenue of $14.45 billion, a 5% year-over-year increase, surpassing Wall Street expectations. Growth was driven by oncology and other recently launched products, which offset steep declines in COVID-19 vaccine and treatment sales.
Key facts
- Revenue reached $14.45 billion
- Revenue up 5% year-over-year
- Oncology and new products drove growth
- COVID product sales declined steeply
- Earnings beat Wall Street expectations
- Q1 2026 results reported
Entities
Institutions
- Pfizer
Sources
- Quartz —